

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | SLF1081851 operates as a Spns2 inhibitor, impeding S1P release (IC50=1.93 μM). This compound holds significant importance in the development and immune system[1][2]. |
| 体内研究 | SLF1081851, administered intraperitoneally at a dose of 20 mg/kg, 4 hours postdose, significantly suppresses circulating lymphocytes and plasma S1P levels, while also reproducing the genetic phenotype observed in Spns2 null mice[1]. |
| 体外研究 | Sphingosine 1-phosphate (S1P) serves as a multifaceted signaling molecule, while Spns2 is responsible for preserving lymph S1P levels[1]. SLF1081851 (0-5 μM; 18-20 h) hinders S1P release, displaying an IC50 value of 1.93 μM in Hela cells[1]. SLF1081851 (0-30 μM; 20 min) dose-dependently inhibits both mSphK1 (recombinant mouse SphK) (at 10 μM) and mSphK2 (at 5 μM), indicating at least 15-fold selectivity[1]. |
| Concentration | Treated Time | Description | References | |
| Human aortic smooth muscle cells (HAoSMCs) | 3 µM | 11 days | SLF1081851 significantly reduced HAoSMC calcification under calcifying conditions. | Pflugers Arch. 2025 Jun;477(6):815-826 |
| HeLa cells | 1.93 µM (IC50) | 18-20 hours | To evaluate the inhibitory effect of SLF1081851 on S1P release, showing an IC50 of 1.93 μM. | J Med Chem. 2022 Jun 9;65(11):7656-7681 |
| Human aortic smooth muscle cells (HAoSMCs) | 3 µM | 48 hours | SLF1081851 significantly suppressed calcification medium-induced CBFA1 and ALPL mRNA expression in HAoSMCs and reduced HAoSMC calcification. | Pflugers Arch. 2025 Jun;477(6):815-826 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | C57BL/6j strain | Intraperitoneal injection | 10 mg/kg | Single dose | To evaluate the effect of SLF1081851 on lymphopenia and plasma S1P levels in mice. | J Med Chem. 2023 Apr 27;66(8):5873-5891 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.91mL 0.58mL 0.29mL |
14.56mL 2.91mL 1.46mL |
29.11mL 5.82mL 2.91mL |
|
| CAS号 | 2763730-97-6 |
| 分子式 | C21H33N3O |
| 分子量 | 343.51 |
| SMILES Code | NCCCC1=NC(C2=CC=C(CCCCCCCCCC)C=C2)=NO1 |
| MDL No. | MFCD34676462 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
| 溶解方案 |
无水乙醇: 8 mg/mL(23.29 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1